benserazide has been researched along with Dyskinesia, Drug-Induced in 65 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Due to a lower bioavailability of the slow release formulation--the latter is based on the "hydrodynamically balanced system" (HBS)--, the patients remained initially on their time schedule of drug intake but received a higher dose of L-DOPA slow release compared to the preceding L-DOPA standard therapy." | 5.29 | [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. ( Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C, 1995) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ-8 scores compared to treatment with levodopa/carbidopa (mean difference 1." | 2.74 | Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. ( Fung, VS; Herawati, L; Wan, Y, 2009) |
| " Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half life, thereby prolonging the efficacy of levodopa." | 2.69 | Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. ( Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G, 1998) |
| "5%, probably reflecting some differences in the bioavailability of the various galenical formulations, and the mean daily drug intakes were reduced from 5." | 2.68 | Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group. ( Gachoud, JP; Gasser, U; Ghika, J, 1997) |
| " However, its long-term use is limited due to motor complications such as wearing-off and dyskinesia." | 1.48 | Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements. ( Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H, 2018) |
| " We used the 6-hydroxydopamine (6-OHDA) rat model of PD treated with a three-week dosing regimen of L-DOPA plus the dopa decarboxylase inhibitor benserazide (4 mg/kg and 7." | 1.43 | Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat. ( Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM, 2016) |
| "Nicotine treatment also decreased AIMs by ~50% in wildtype mice, although not in α6⁻/⁻ mice." | 1.38 | Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. ( Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M, 2012) |
| " However, long-term administration of levodopa induces motor complications, such as levodopa-induced dyskinesia." | 1.38 | Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. ( Cai, Y; Liao, M; Liu, Z; Yang, X; Yuan, W; Zheng, R, 2012) |
| " Half-life was 58." | 1.38 | L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ( Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Unfortunately, with disease progression, levodopa reduces Parkinsonism at the cost of evoking abnormal involuntary movements known as levodopa-induced dyskinesia (LID)." | 1.36 | Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats. ( Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W, 2010) |
| " Based on the results of rotational behavior and forelimb hyperkinesia in Week 5, the rats were allocated to three treatment groups (saline and two dosing rates of piclozotan set at 0." | 1.36 | Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. ( Inoue, T; Koyama, M; Ogata, A; Tani, Y, 2010) |
| " Catechol-O-methyltransferase (COMT) inhibitors increase the half-life and bioavailability of levodopa, providing more continuous dopamine receptor stimulation." | 1.33 | Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. ( Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E, 2005) |
| " Due to a lower bioavailability of the slow release formulation--the latter is based on the "hydrodynamically balanced system" (HBS)--, the patients remained initially on their time schedule of drug intake but received a higher dose of L-DOPA slow release compared to the preceding L-DOPA standard therapy." | 1.29 | [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. ( Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C, 1995) |
| " As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened." | 1.29 | Clinical implications of sustained dopaminergic stimulation. ( Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F, 1994) |
| " Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side." | 1.28 | [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys]. ( Chen, S, 1992) |
| "Fifty four patients with idiopathic Parkinson's disease receiving levodopa therapy were studied." | 1.28 | Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. ( Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC, 1990) |
| "A number of patients with Parkinson's disease complain of severe and distressing pain." | 1.27 | Painful Parkinson's disease. ( Koller, WC; Lang, AE; Marsden, CD; Quinn, NP, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (16.92) | 18.7374 |
| 1990's | 8 (12.31) | 18.2507 |
| 2000's | 14 (21.54) | 29.6817 |
| 2010's | 30 (46.15) | 24.3611 |
| 2020's | 2 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| Murakami, Y | 1 |
| Nishijima, H | 1 |
| Nakamura, T | 1 |
| Furukawa, T | 1 |
| Kinoshita, I | 1 |
| Kon, T | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Speck, AE | 1 |
| Aguiar, AS | 1 |
| Ferreira, SG | 1 |
| Silva, HB | 1 |
| Tomé, ÂR | 1 |
| Agostinho, P | 1 |
| Cunha, RA | 1 |
| Prediger, RD | 1 |
| Cilia, R | 1 |
| Laguna, J | 1 |
| Cassani, E | 1 |
| Cereda, E | 1 |
| Pozzi, NG | 2 |
| Isaias, IU | 2 |
| Contin, M | 1 |
| Barichella, M | 1 |
| Pezzoli, G | 2 |
| Tsunekawa, H | 1 |
| Takahata, K | 1 |
| Okano, M | 1 |
| Ishikawa, T | 1 |
| Satoyoshi, H | 1 |
| Nishimura, T | 1 |
| Hoshino, N | 1 |
| Muraoka, S | 1 |
| Turco, F | 1 |
| Canessa, A | 1 |
| Olivieri, C | 1 |
| Palmisano, C | 1 |
| Arnulfo, G | 1 |
| Marotta, G | 1 |
| Volkmann, J | 1 |
| Lopez, S | 1 |
| Bonito-Oliva, A | 1 |
| Pallottino, S | 1 |
| Acher, F | 1 |
| Fisone, G | 1 |
| Cote, SR | 1 |
| Chitravanshi, VC | 1 |
| Bleickardt, C | 1 |
| Sapru, HN | 1 |
| Kuzhikandathil, EV | 1 |
| Morin, N | 1 |
| Morissette, M | 2 |
| Grégoire, L | 3 |
| Di Paolo, T | 2 |
| Solís, O | 1 |
| Espadas, I | 1 |
| Del-Bel, EA | 1 |
| Moratalla, R | 1 |
| Gellhaar, S | 1 |
| Marcellino, D | 1 |
| Abrams, MB | 1 |
| Galter, D | 1 |
| Bordia, T | 1 |
| McGregor, M | 1 |
| McIntosh, JM | 2 |
| Drenan, RM | 1 |
| Quik, M | 2 |
| Shan, L | 1 |
| Diaz, O | 1 |
| Zhang, Y | 1 |
| Ladenheim, B | 1 |
| Cadet, JL | 1 |
| Chiang, YH | 1 |
| Olson, L | 1 |
| Hoffer, BJ | 1 |
| Bäckman, CM | 1 |
| Smith, LM | 1 |
| Parr-Brownlie, LC | 1 |
| Duncan, EJ | 1 |
| Black, MA | 1 |
| Gemmell, NJ | 1 |
| Dearden, PK | 1 |
| Reynolds, JN | 1 |
| Fung, VS | 1 |
| Herawati, L | 1 |
| Wan, Y | 1 |
| Buck, K | 2 |
| Ferger, B | 2 |
| Marin, C | 2 |
| Aguilar, E | 2 |
| Rodríguez-Oroz, MC | 1 |
| Bartoszyk, GD | 1 |
| Obeso, JA | 2 |
| Pérez-Rial, S | 1 |
| García-Gutiérrez, MS | 1 |
| Molina, JA | 1 |
| Pérez-Nievas, BG | 1 |
| Ledent, C | 1 |
| Leiva, C | 1 |
| Leza, JC | 1 |
| Manzanares, J | 1 |
| Berton, O | 1 |
| Guigoni, C | 1 |
| Li, Q | 1 |
| Bioulac, BH | 1 |
| Aubert, I | 1 |
| Gross, CE | 1 |
| Dileone, RJ | 1 |
| Nestler, EJ | 1 |
| Bezard, E | 1 |
| Kobylecki, C | 1 |
| Cenci, MA | 2 |
| Crossman, AR | 1 |
| Ravenscroft, P | 1 |
| Alachkar, A | 1 |
| Brotchie, JM | 2 |
| Jones, OT | 1 |
| Lieu, CA | 1 |
| Kunselman, AR | 1 |
| Manyam, BV | 1 |
| Venkiteswaran, K | 1 |
| Subramanian, T | 1 |
| Yang, X | 3 |
| Yuan, W | 3 |
| Ren, T | 1 |
| Song, L | 2 |
| Wu, N | 2 |
| Liu, Z | 4 |
| Tani, Y | 1 |
| Ogata, A | 1 |
| Koyama, M | 1 |
| Inoue, T | 1 |
| Spinnewyn, B | 1 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 1 |
| Auguet, M | 1 |
| Gil, SJ | 1 |
| Park, CH | 1 |
| Lee, JE | 1 |
| Minn, YK | 1 |
| Koh, HC | 1 |
| Dupre, KB | 1 |
| Ostock, CY | 1 |
| Eskow Jaunarajs, KL | 1 |
| Button, T | 1 |
| Savage, LM | 1 |
| Wolf, W | 1 |
| Bishop, C | 1 |
| Ohlin, KE | 1 |
| Francardo, V | 1 |
| Lindgren, HS | 1 |
| Sillivan, SE | 1 |
| O'Sullivan, SS | 1 |
| Luksik, AS | 1 |
| Vassoler, FM | 1 |
| Lees, AJ | 1 |
| Konradi, C | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 1 |
| Nepoklonov, AV | 1 |
| Kokshenev, II | 1 |
| Voronina, TA | 1 |
| Val'dman, EA | 1 |
| Yin, LL | 1 |
| Geng, XC | 1 |
| Zhu, XZ | 1 |
| Alcacer, C | 1 |
| Santini, E | 1 |
| Valjent, E | 1 |
| Gaven, F | 1 |
| Girault, JA | 1 |
| Hervé, D | 1 |
| Park, KM | 1 |
| Hrachova, M | 1 |
| Mallela, A | 1 |
| Huang, LZ | 1 |
| Grady, SR | 1 |
| Gerlach, M | 1 |
| Halley, P | 1 |
| Riederer, P | 1 |
| van den Buuse, M | 1 |
| Zheng, R | 1 |
| Cai, Y | 1 |
| Liao, M | 1 |
| Huot, P | 1 |
| Johnston, TH | 1 |
| Koprich, JB | 1 |
| Fox, SH | 2 |
| Chen, Y | 1 |
| Hong, X | 1 |
| Nevalainen, N | 1 |
| Lundblad, M | 1 |
| Gerhardt, GA | 1 |
| Strömberg, I | 1 |
| Klintenberg, R | 1 |
| Svenningsson, P | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Henry, B | 1 |
| Hill, M | 1 |
| Crossman, A | 1 |
| Brotchie, J | 1 |
| Bonastre, M | 1 |
| Tolosa, E | 1 |
| Dridi, M | 1 |
| Calon, F | 1 |
| Hadj Tahar, A | 3 |
| Meltzer, LT | 1 |
| Bédard, PJ | 3 |
| Solla, P | 1 |
| Floris, G | 1 |
| Tacconi, P | 1 |
| Cannas, A | 1 |
| Fleming, SM | 1 |
| Salcedo, J | 1 |
| Hutson, CB | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| Levine, MS | 1 |
| Chesselet, MF | 1 |
| Ba, M | 1 |
| Kong, M | 1 |
| Ma, G | 1 |
| Yang, H | 1 |
| Lu, G | 1 |
| Chen, S | 2 |
| Bjørndal, N | 2 |
| Casey, D | 1 |
| Gerlach, J | 3 |
| Casey, DE | 2 |
| Eichhorn, TE | 1 |
| Schrag, A | 1 |
| Trenkwalder, C | 1 |
| Selzer, R | 1 |
| Kohnen, R | 1 |
| Oertel, WH | 2 |
| Poewe, W | 2 |
| Ghika, J | 2 |
| Gachoud, JP | 1 |
| Gasser, U | 1 |
| Stocchi, F | 1 |
| Patsalos, PN | 1 |
| Berardelli, A | 1 |
| Barbato, L | 1 |
| Bonamartini, A | 1 |
| Manfredi, M | 1 |
| Ruggieri, S | 1 |
| Baas, H | 1 |
| Beiske, AG | 1 |
| Jackson, M | 1 |
| Ransmayr, G | 1 |
| Bélanger, N | 1 |
| Bangassoro, E | 2 |
| Ekesbo, A | 1 |
| Svensson, KA | 1 |
| Tedroff, J | 1 |
| Yokochi, M | 1 |
| Kondo, T | 1 |
| Hirayama, K | 1 |
| Narabayashi, H | 1 |
| Kuruma, I | 1 |
| Feuerstein, C | 2 |
| Serre, F | 2 |
| Gavend, M | 2 |
| Pellat, J | 2 |
| Perret, J | 2 |
| Tanche, M | 2 |
| Lhermitte, F | 1 |
| Agid, Y | 1 |
| Signoret, JL | 1 |
| Studler, JM | 1 |
| Jenkins, JR | 1 |
| Pearce, JM | 1 |
| Díaz, F | 1 |
| Chaná, P | 1 |
| Horstink, MW | 1 |
| Zijlmans, JC | 1 |
| Pasman, JW | 1 |
| Berger, HJ | 1 |
| van't Hof, MA | 1 |
| Quinn, NP | 1 |
| Koller, WC | 1 |
| Lang, AE | 1 |
| Marsden, CD | 1 |
| Mondal, BK | 1 |
| Mondal, KN | 1 |
| Wermuth, L | 1 |
| Lieberman, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.[NCT02680977] | Phase 2 | 18 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET[NCT02578849] | 45 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease[NCT03639064] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for benserazide and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Topics: Antiparkinson Agents; Benserazide; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, D | 2017 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catecho | 2009 |
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 1997 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dia | 1998 |
61 other studies available for benserazide and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine | 2021 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Ther | 2018 |
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Dr | 2018 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dise | 2011 |
Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzopyrans; Corpus Striatum; Dependovirus; Dopamine; Do | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dop | 2015 |
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskin | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Diseas | 2015 |
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, | 2015 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskin | 2016 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dys | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-In | 2011 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, A | 2009 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix | 2010 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxyla | 2010 |
A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Disease Models, Anima | 2010 |
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease | 2010 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Ag | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Ch | 2011 |
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkins | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; D | 2011 |
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Inter | 2012 |
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Do | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; Dopamine and cAMP-Regulated Phosphoprotein 32; Dr | 2012 |
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability | 2012 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease | 2012 |
Striatal glutamate release in L-DOPA-induced dyskinetic animals.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; | 2013 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix | 2002 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catecho | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, C | 2006 |
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Homeostasis; | 2006 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Mo | 2006 |
Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Ben | 2008 |
Dopamine antagonist and agonist treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benserazide; Benzimidazoles; Dopamine; Dopamine Antagonists; Dyskinesia, Drug- | 1980 |
Levodopa and receptor sensitivity modification in tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Bipolar Disorder; Dementia; Dose-Response Relationsh | 1982 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; | 1983 |
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relations | 1995 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dys | 1994 |
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Clozapine; Dose- | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine A | 2001 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Dopa Decarbo | 1979 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methy | 1977 |
["Beginning and end of dose" dyskinesias caused by L-DOPA].
Topics: Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodo | 1977 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carbo | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Hu | 1992 |
[Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
Topics: Aged; Benserazide; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced | 1991 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug | 1990 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedu | 1986 |
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug- | 1986 |
Outpatient treatment of Parkinson's disease.
Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Ind | 1988 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |